Acacia Research Corporation (Nasdaq: ACTG) announced today that a subsidiary has acquired rights to patents in the orthopedic technology sector.
“Acacia continues to increase the number of patent portfolios we control in the medical device and diagnostics sectors,” commented Paul Ryan, CEO.
ABOUT ACACIA RESEARCH CORPORATION
Acacia Research Corporation’s subsidiaries partner with inventors and patent owners, license the patents to corporate users, and share the revenue. Acacia Research Corporation’s subsidiaries control 250 patent portfolios, covering technologies used in a wide variety of industries.
Information about Acacia Research Corporation and its subsidiaries is available at
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This news release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995.
These statements are based upon our current expectations and speak only as of the date hereof.
Our ability to continue increasing the number of patent portfolios in the medical device and diagnostics sectors, and our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, the
ability to successfully develop licensing programs and attract new business within the medical field, rapid technological change in relevant
markets, changes in demand for current and future intellectual property rights, legislative, regulatory and competitive developments addressing licensing and enforcement of patents and/or intellectual property in general, and general economic conditions.
Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition.
We undertake no obligation to revise or update publicly any forward-looking statements for any reason.